Evoke Pharma Highlights GIMOTI As A Leading Solution For Gastroparesis Treatment As Domperidone Supply Ends; FDA Posts Update As Mechanism To Obtain Unapproved Domperidone Expected To Lose Supply In Early 2025
Evoke Pharma Highlights GIMOTI As A Leading Solution For Gastroparesis Treatment As Domperidone Supply Ends; FDA Posts Update As Mechanism To Obtain Unapproved Domperidone Expected To Lose Supply In Early 2025
FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025
FDA發佈更新，預計未獲批准的多潘立酮將在2025年初失去供應
Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to oral metoclopramide
Gimoti仍然是唯一被批准的藥物，顯示出與口服美托克拉米德相比可以減少住院、急診室和醫療辦公室就診及相關費用
SOLANA BEACH, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray, underscores its commitment to patients and healthcare providers managing gastroparesis in light of FDA's recent update regarding domperidone supply. As the sole FDA-approved nasal spray treatment for acute and recurrent diabetic gastroparesis in adults, GIMOTI (metoclopramide) is uniquely positioned to address the ongoing needs of patients facing challenges with alternative therapies.
加州索拉納海灘，2024年12月19日（GLOBE NEWSWIRE）-- Evoke Pharma, Inc.（納斯達克：EVOK）是一家專注於治療胃腸疾病的特種藥品公司，主要強調GIMOTI（美托克拉米德）鼻噴霧劑，重申其對患者和醫療提供者在FDA最近關於多潘立酮供應更新的背景下管理胃輕癱的承諾。作爲FDA批准的唯一用於治療成人急性和複發性糖尿病胃輕癱的鼻噴霧劑，GIMOTI（美托克拉米德）在滿足面臨替代療法挑戰的患者持續需求方面具有獨特的優勢。
譯文內容由第三人軟體翻譯。